Pymedix is developing fully-automated machine perception technologies for medical imaging that utilize advanced algorithms for enhanced image analysis and interpretation. This technology improves diagnostic accuracy and efficiency by eliminating the inconsistencies and time delays associated with manual image evaluation.
Funding
$290K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Manual medical image registration and analysis in radiotherapy planning is time-consuming and prone to inconsistencies, potentially impacting diagnostic accuracy and treatment effectiveness. Existing image registration software often requires significant manual adjustments and lacks the speed and reliability needed for personalized cancer treatment.
Solution
Pymedix offers Autofuse, an FDA-cleared, fully automated 3D deformable image registration (DIR) software designed to enhance radiotherapy planning. Autofuse leverages machine perception technologies, extending concepts from 2D vision into 3D, to improve the speed, accuracy, and consistency of image correlation and data fusion. The software automates image registration, dose deformation, and uncertainty estimation, eliminating variability and streamlining workflows for physicians, dosimetrists, and physicists. By focusing computing effort on critical image areas, Autofuse makes tasks like global image search computationally efficient, enabling better, more personalized cancer treatment.
Target Audience
The primary target audience includes physicians, dosimetrists, and physicists involved in radiation treatment planning, as well as hospitals and cancer centers seeking to improve workflow efficiency and treatment accuracy.
Features
- Fully automated 3D deformable image registration (DIR)
- Machine perception technology mimicking the human visual cortex
- Streamlined interface with powerful contouring tools
- Automatic structure propagation for accelerated adaptive planning
- Multi-image fusion capabilities
- Dose deformation and uncertainty estimation
- FDA-cleared for clinical use